Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Top Page
RxSight
(NASDAQ:RXST)
Rating:43Neutral
Price Target:
$12.50
▼(-19.51%Downside)
Positive Factors
International Expansion
International markets represent a significant opportunity for RXST, with plans to enter European and Asian markets where the advanced technology IOL market is twice the size of the US market.
Market Position
RXST has a strong first-mover advantage in the light adjustable lenses market, having captured about 10% of the advanced technology intraocular lens market since its launch.
Valuation
RXST's valuation appears very attractive, trading at a significant discount to its peers, with above-average growth, a strong moat, and high gross margins.
Negative Factors
Competition
Competition and consumer confidence are risks as other companies are launching competing AT-IOLs in the US, potentially impacting RXST’s growth.
Revenue Performance
RXST reported 1Q25 revenue of $37.9M, which was below initial consensus estimates by around 4.7%.
Utilization
Overall utilization per system per month decreased by 6% year-over-year.
RxSight (RXST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$631.09M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth46.69%
EPS Growth46.68%
CountryUS
Employees498
SectorHealthcare
Sector Strength39
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.20
Shares Outstanding40,636,982
10 Day Avg. Volume860,531
30 Day Avg. Volume1,079,553
Financial Highlights & Ratios
PEG Ratio-1.45
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-23.62
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda-4.36
Forecast
1Y Price Target
$22.56Price Target Upside45.27% Upside
Rating ConsensusHold
Number of Analyst Covering9
RxSight Business Overview & Revenue Model
Company DescriptionRxSight, Inc. (RXST) operates in the healthcare sector, focusing on ophthalmic innovations. The company is known for its development and commercialization of the Light Adjustable Lens (LAL), a breakthrough in cataract surgery that allows for postoperative vision adjustments to improve patient outcomes. RxSight is committed to enhancing vision care through advanced technology and improving the quality of life for patients undergoing cataract surgeries.
How the Company Makes MoneyRxSight generates revenue primarily through the sale of its Light Adjustable Lens (LAL) and associated Light Delivery Device (LDD) systems. These products are sold to ophthalmologists and eye surgery centers, providing a unique value proposition by enabling customized vision correction after cataract surgery. The company also earns revenue from service agreements and follow-up care related to its product offerings. Strategic partnerships with eye care professionals and healthcare facilities further enhance RxSight's market reach and revenue potential.
RxSight Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 4.23%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Neutral
The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.Q1-2025 Updates
Positive Updates
Revenue Growth
Preliminary first quarter 2025 revenue was $37.9 million, up 28% compared to the year-ago quarter.
European Regulatory Approval
RxSight reported European regulatory approval for their LDD and LAL, marking a significant step towards expanding into the EU market.
Customer Satisfaction
Customer satisfaction reached an all-time high of 97%, indicating strong approval of RxSight's products and services.
LDD Installed Base Growth
The LDD installed base grew to 1,044 units, up 43% compared to the end of the first quarter of 2024.
Negative Updates
Revenue Guidance Revision
The full-year revenue guidance was reduced from $185 million-$197 million to $160 million-$175 million, indicating a decrease in expected growth from 32%-41% to 14%-25%.
Sequential Revenue Decline
Revenue for Q1 2025 was down 6% sequentially from Q4 2024.
Premium IOL Market Softening
The premium IOL market experienced a decline, affected by macroeconomic factors and competitive launches, causing a year-over-year drop in same-store LAL sales.
LAL Sales Decline
LAL sales were 27,579, up 36% year-over-year but sequentially down 5% from Q4 2024.
Operating Expense Guidance Increase
Operating expense guidance was adjusted higher to $150 million-$160 million due to increased customer interaction costs.
Company Guidance
During the recent RxSight conference call, the company provided revised guidance for fiscal year 2025, reflecting anticipated revenue in the range of $160 million to $175 million, down from the previous estimate of $185 million to $197 million. This adjustment reflects an implied revenue growth of 14% to 25% compared to 2024, a reduction from the initial 32% to 41% growth projection. The company anticipates selling more Light Delivery Devices (LDDs) in 2025 than in 2024, despite potential economic headwinds affecting Light Adjustable Lens (LAL) procedures. First-quarter 2025 revenue was reported at $37.9 million, marking a 28% increase from the same period in the previous year but a 6% sequential decline from the fourth quarter of 2024. The gross margin guidance remains unchanged at 71% to 73%, while operating expenses are adjusted to $150 million to $160 million, down from the prior forecast of $165 million to $170 million, reflecting a focus on aligning expenses with revenue growth.RxSight Financial Statement Overview
Summary
RxSight shows promising revenue and gross profit growth, with a sound equity position. However, profitability and cash flow generation remain significant challenges, which the company needs to address to ensure long-term financial health. Investors should monitor the company's progress in achieving profitability and improving cash flow dynamics.Income Statement
RxSight has demonstrated strong revenue growth, with a 57% increase from 2023 to 2024. The gross profit margin improved to 70.7%, indicating efficient production and sales processes. However, the company remains unprofitable, with negative net and EBIT margins, pointing to ongoing challenges in controlling operating expenses.65
Positive
Balance Sheet
The balance sheet is characterized by a high equity ratio of 88.3%, suggesting strong capitalization. However, the company has no net debt, which is a positive sign, but the negative stockholders' equity in earlier years and fluctuating liabilities present potential risks, despite recent improvements in equity.55
Neutral
Cash Flow
Cash flow metrics highlight concerns, with zero operating cash flow in 2024, indicating challenges in generating cash from operations. Despite this, the company has managed to secure financing to support its activities, evidenced by positive financing cash flows. The absence of free cash flow growth is a concern for long-term sustainability.45
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 139.93M | 89.08M | 49.01M | 22.59M | 14.68M | Gross Profit |
| 98.94M | 53.77M | 21.33M | 4.52M | 1.71M | EBIT |
| -36.86M | -50.09M | -63.32M | -52.79M | -35.41M | EBITDA |
| -23.76M | -41.04M | -57.78M | -41.01M | 32.15M | Net Income Common Stockholders |
| -27.45M | -48.61M | -66.76M | -48.69M | 27.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 237.22M | 127.18M | 105.80M | 159.33M | 68.97M | Total Assets |
| 318.56M | 182.55M | 150.16M | 192.72M | 100.68M | Total Debt |
| 12.30M | 3.01M | 44.99M | 44.93M | 30.75M | Net Debt |
| -4.41M | -6.68M | 33.16M | 20.57M | 16.76M | Total Liabilities |
| 37.33M | 22.19M | 60.26M | 54.48M | 398.21M | Stockholders Equity |
| 281.24M | 160.36M | 89.90M | 138.24M | -297.53M |
| Cash Flow | Free Cash Flow | |||
| -22.39M | -46.41M | -61.24M | -46.65M | -37.74M | Operating Cash Flow |
| -16.95M | -41.59M | -58.85M | -44.71M | -35.20M | Investing Cash Flow |
| -99.31M | -22.13M | 39.95M | -81.91M | 15.59M | Financing Cash Flow |
| 123.32M | 61.52M | 6.33M | 137.34M | 25.24M |
RxSight Technical Analysis
Neutral
15.53
Price Trends
16.61
Negative
23.20
Negative
35.27
Negative
Market Momentum
-0.11
Negative
50.82
Neutral
41.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RXST, the sentiment is Neutral. The current price of 15.53 is above the 20-day moving average (MA) of 14.92, below the 50-day MA of 16.61, and below the 200-day MA of 35.27, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 50.82 is Neutral, neither overbought nor oversold. The STOCH value of 41.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RXST.
RxSight Risk Analysis
RxSight disclosed 87 risk factors in its most recent earnings report. RxSight reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RxSight Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $803.71M | ― | -15.96% | ― | 22.60% | 41.26% | |
53 Neutral | $5.23B | 3.23 | -44.27% | 2.82% | 16.82% | 0.11% | |
52 Neutral | $499.62M | ― | -7.22% | ― | 18.81% | 67.41% | |
52 Neutral | $620.94M | ― | 26.25% | ― | ― | ― | |
47 Neutral | $424.72M | ― | -27.82% | ― | 5.85% | -8.92% | |
47 Neutral | $529.01M | ― | -19.79% | ― | 8.60% | -42.76% | |
43 Neutral | $631.09M | ― | -11.98% | ― | 46.69% | 46.68% |
* Healthcare Sector Average
Performance Comparison
RXST
RxSight
15.81
-41.22
-72.28%
OFIX
Orthofix
11.03
-2.75
-19.96%
AXGN
AxoGen
11.36
4.50
65.60%
SIBN
SI-Bone
18.90
5.15
37.45%
BVS
Bioventus
6.66
-0.04
-0.60%
CBLL
Ceribell, Inc.
16.93
-8.57
-33.61%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.